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INTRODUCTION 
Oral route is considered most natural, 
uncomplicated,convenient and safe due to its ease of 
administration, patient acceptance and cost‐effective 
manufacturing process. Floating Drug Delivery Systems 
(FDDS) have a bulk density lower than gastric fluids and thus 
remain buoyant in the stomach for a prolonged period of 
time,without affecting the gastric emptying rate. This results in 
an increase in the Gastro Retentive Time and a better control of 
fluctuations in the plasma drug concentrations.
1
 Floating 
systems can be classified into two distinct categories, 
non‐effervescent and effervescent systems. The gastric 
emptying time has been reported to be from 2-6h in humans in 
the fed state. When a sustained release dosage form is 
administered orally, sufficient bioavailability could not be 
obtained, especially for drugs having a limited absorption site in 
the intestinal tract. Therefore modern oral controlled release 
dosage forms must be based on gastrointestinal physiology, so 
that the drug is fully available for absorption
2-3 
Stomach specific floating drug delivery 
Stomach Specific FDDS have a bulk density less than 
gastric fluids and so remain buoyant in the stomach without 
affecting the gastric emptying rate for a prolonged period of 
time. While the system is floating on the gastric contents, the 
drug is released slowly at the desired rate from the system. After 
release of drug, the residual system is emptied from the 
stomach. This results in an increased GRT and a better control 
of fluctuations in plasma drug concentration. The floating 
sustained release dosage forms present most of the 
characteristics of hydrophilic matrices and are known as 
„hydrodynamically balanced systems‟ („HBS‟) since they are 
able to maintain their low apparent density, while the polymer 
hydrates and builds a gelled barrier at the outer surface. The 
drug is released progressively from the swollen matrix.
4-5 
 Itopride hydrochloride is a novel gastroprokinetic 
drug, widely absorbed from the stomach and upper part of the 
small intestine and absorption becomes less as the drug passes 
beyond this. The bioavailability can be improved by making the 
drug completely absorbed in the stomach and upper part of the 
small intestine. It has a half life of 6hrs. The short half life of 
Itopride hydrochloride necessitates frequent administration. 
Therefore it is highly desirable to have a controlled release 
dosage form for Itopride hydrochloride
6 
Gastric emptying 
Gastric emptying occurs during fasting as well as fed 
states. The pattern of motility is however distinct in the 2 states. 
During the fasting state an interdigestive series of electrical 
events take place, which cycle both through stomach and 
intestine every 2 - 3 hours . This is called the 
interdigestivemyloelectric cycle or migrating myloelectric cycle 
(MMC), which is further divided into following 4 phases as 
described by Wilson and Washington. PHASE I the quiescent 
period, lasts from 30 to 60 mins and is characterized by a lack 
of secretary, electrical and contractile activity. PHASE II, 
exhibits intermittent activity for 20-40 min, during which the 
contractile motions increase in frequency and size. Bile enters 
the duodenum during this phase, whereas gastric mucus 
discharge occurs during the latter part of phase II and 
throughout phase III. PHASE III is a short period of intense 
large regular contractions, termed “housekeeper waves” that 
sweep off undigested food and last 10-20 min. PHASE IV is the 
transition period of 0-5 mins between Phase III & I .
7-8 
Factors affecting gastric emptying 
The most important parameters affecting gastric 
emptying and, hence, the gastric retention time oforal dosage 
forms include:Density, Size, Shape of dosage form, Single or 
Multiple unit formulation, Fed or Unfed state, Nature of Meal 
Gender, Age ,Biological factors, Frequency of Feed etc
9-10 
In the present study HPMC K4M, Xanthan Gum, 
Sodium Bicarbonate, Citric acid, Lactose was used for 
formulating floating drug delivery system. When tablet reaches 
to gastric fluid, it floats due to effervescence produced by 
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Sodium Bicarbonate & Citric acid. Drug release controlled by 
HPMC K4M Xanthan Gum due to their swelling &release 
retarding properties.The proposed formulation can be 
manufactured using currently available 
pharmaceuticaltechnology and materials recognized as safe. 
MATERIALS & METHOD 
Materials  
Itopride HCL was purchased from Leo Chem 
researcher resources Ltd. Bangalore (India). HPMC K4M and 
Xanthan gum were obtained From Research lab Fine chem. 
(India).Other excipientsused to prepare the tablets were either of 
analytical or pharmaceutical grades purchased from local 
market. 
Method 
Drug Excipients Compatibility Study  
Sample of pure drug, physical mixture of excipients 
and drug in (1 : 1) ratio was placed at accelerated stability 
condition 40±2 °C and 75±5% relative humidity for a period of 
3 month. At the end of 3 month samples were evaluated for 
drug–excipients compatibility using Differential scanning 
colorimeter (DSC) (Mettler Toledo DSC 822e, Japan) and 
Fourier transformed infrared spectroscopy (FT-IR) (Shimadzu 
Corporation, Japan, 8400s). 
Formulation of floating tablets 
Floating tablets of itopride hydrochloride were 
prepared by direct compression method. The composition of 
formulation is given in the Table 1. ItoprideHCl, lactose and 
hydrophilic polymers were passed from sieve of # 40 and mixed 
for 10 min. All the Ingredients were weighed 
accurately.ItoprideHCl, lactose and hydrophilic polymers were 
passed from sieve of # 40 and mixed for 10 min blended in 
glass mortar uniformly. Then remaining excipients were also 
passed sieve of # 60 & mixed with drug blend. After sufficient 
mixing, powder blend was compressed into tablets on a  12 
station single punch rotary tablet compression machine. A 
concave faced punch 10mm in diameter were used for tableting. 
Compression force of the machine was adjusted to obtain the 
hardness of 5 kg/cm2 and 7kg/cm2 for different batches. 
 
Table 1: Composition of all the formulations (Batch F1 – Batch F9) 
All ingredients are in mg. 
3
2
 Full Factorial Design 
A 3
2
 randomized full factorial design was used in this study. In this design2 factors were evaluated, each at 3 levels, 
and experimental trials were performed at all 9 possible combinations. The amount of HPMC(X1) and Amount of Xanthan 
Gum (X2) were selected as independent variables. The times required to float, swelling index & % release   were selected as 
dependent variables. The experimental design with corresponding formulation outline in Table 2. 
Table 2: Composition of formulations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BATCH ITOPRIDE HPMC 
K 4M 
XANTHAN 
GUM 
NaHCO3 CITRIC 
ACID 
LACTOSE Mg. 
STERATE 
TOTAL 
F1 100 120 50 100 70 106 4 550 
F2 100 120 70 100 70 86 4 550 
F3 100 120 90 100 70 66 4 550 
F4 100 140 70 100 70 66 4 550 
F5 100 140 50 100 70 86 4 550 
F6 100 140 90 100 70 46 4 550 
F7 100 160 50 100 70 66 4 550 
F8 100 160 70 100 70 46 4 550 
F9 100 160 90 100 70 26 4 550 
Batch code X1 X2 
F1 -1 -1 
F2 -1 0 
F3 -1 1 
F4 0 0 
F5 0 -1 
F6 0 1 
F7 1 -1 
F8 1 0 
F9 1 1 
Levels Amount of HPMC (X1) Amount of Xanthan Gum (X2) 
-1 120 50 
0 140 70 
1 160 90 
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EVALUATION  
Thickness:  
Thickness of tablets was determined using Vernier 
caliper. Five tablets from batch wereused, and average 
values were calculated.
11-12 
Weight variation test 
To determine average weight, each tablet from 
formulation was weighed using an electronic balance (AUX-
220, Shimadzu).
11-12
 
Hardness:  
The hardness was tested using Monsanto tester. The 
force is measured in kilograms.
11-12
 
Friability: 
 
For each formulation, the friability of 6 tablets was 
determined using the Roche friabilator (Lab Hosp.).
11-12
 
 
In vitro drug release study of floating tablets 
In-vitro dissolution studies were performed on 
floating tablets prepared by direct compression method using 
0.1N HCL for 12 hrs. USP apparatus II with the paddle 
speed 50 rpm. 1 ml of filtered aliquot was withdrawn at pre-
determined time intervals and replaced with 1 ml maintained 
at the same temperature. The samples were analyzed at 258 
nm using a UV spectrophotometer. The floating lag time and 
percentage release was determined for the each 
formulation.
13-14 
RESULT AND DISCUSSION: 
Compatability study 
Drug-Excipient Interactions: 
The IR spectra of Formulation were compared with 
the standard spectrum of Itopride HCL (Fig. 1). IR spectrum 
of  was  Itopride HCL characterized by the absorption of-
C=O group at 1662 cm−1, –OCH3 group at 1128 cm−1&N-
H Stretching at 3281 cm−1. In spectra of Formulation,band 
was same absorption pattern as that of pure drug. Mentioned 
evidences thus lead to the conclusion that changes were not 
seen as there was no physical interaction between the drug 
and polymers. 
In DSC study also drug was characterized by its 
melting point & formulation was also showing same results 
as drug, by these mentioned evidences lead to the conclusion 
that changes were not seen s there was no physical 
interaction between the drug &polymers (Fig 2). 
 
 
Figure 1: IR Spectrogram of Drug ItoprideHcl&  formulation 
 
Figure 2: DSC Spectrogram of Drug ItoprideHcl (A) & formulation (B) 
Preparation of floating tablets 
Floating tablets were prepared by using 2 
independent variables as different concentrations of 
polymers  by using 3
2 
factorial design. In formulation 
excipients used were HPMC K4M, Xanthan Gum, Sodium 
bicarbonate, Citric Acid, lactose & Magnesium Sterate. 
Carbon dioxide is formed within the tablet containing 
effervescent agent when the tablet is brought in contact with 
the acidic dissolution medium. Sodium bicarbonate is used 
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as gas generating agent which induces floatability of the 
tablet and it makes tablet remain to float in stomach The low 
density of hydroxypropyl methylcellulose assists in floating 
the tablet. Moreover, the gelling capacity of HPMC also 
helps to float the tablet by entrapping carbon dioxide gas in 
the gel network of HPMC. The gelling capacity of HPMC 
prevents disintegration of the tablet during the dissolution 
study.  HPMC was choosen as swellable polymer because it 
is widely used as low-density hydrocolloid system, upon 
contact with water a hydrogel layer would be formed to act 
as a gel boundary for the delivery system, but it would fail to 
retard the release of drug through the matrix because of its 
solubility in stomach pH. Xanthan gum is used in 
combination with HPMC to slow the drug release;xanthan 
gum ability to do this may be caused by the low solubility in 
gastric pH. Lactose is used as filler.  Mg. stearate is used as 
lubricant and glidant to improve flow property of powder 
blend. Swelling index describes the amount of water that is 
contained within the hydrogel at equilibrium and is a 
function of the network structure, hydrophilicity and 
ionization of the functional groups. 
Precompression Parameters: 
Angle of repose (θ): The values obtained for angle of repose 
for all formulations were tabulated in Table no.3The values 
were found to be in the range from 23°.30' to 28°.88'. This 
indicates good flow property of the powder blend for direct 
compression. 
Compressibility index: The values obtained for 
Compressibility index for all formulations were tabulated in 
Table no.3 Compressibility index value ranges between 
11.23% to 18.45% indicating that the powder blend have the 
required flow property. 
Postcompression parameters 
Tablet dimensions 
The dimensions determined for formulated tablets were 
tabulated in Table No.4. Tablets mean thickness (n =3) were 
almost uniform in all the ten formulations and were found to 
be in the range of 5.12 mm to 5.18 mm. The diameter of the 
tablet ranges between 10.00 mm to 10.03mm. 
Table 3: Pre-compression parameters 
Batch Angle of Repose 
(θ) 
Compressibility Index (%) 
F1 24.49 13.34 
F2 23.30 12.98 
F3 27.12 12.30 
F4 27.89 16.29 
F5 28.31 18.45 
F6 28.88 11.23 
F7 25.09 12.67 
F8 27.34 14.30 
F9 24.22 15.33 
 
Hardness test 
 The measured hardness of tablets of each batch ranged 
between 5.5 to 6.5kg/cm2 (Table No.4). This ensures good 
handling characteristics of all batches. 
Friability test   
The values of friability test were tabulated in Table No.4. 
The % friabilitywas less than 1% in all the 
formulationsensuring that the tablets weremechanically 
stable. 
Weight variation test 
The percentage weight variations for all formulations were 
shown in Table No.4. All the tablets passed weight variation 
test as the % weight variation was within the 
Pharmacopoeial limits of ±5% of the weight. The weights of 
all the tablets were found to be uniform with low standard 
deviation values. 
 
Table 4: Postcompression parameters 
 
Swelling Study  
The swelling behavior of a dosage form was 
measured by studying its weight gain or water uptake.The 
dimensional changes could be measured in terms of the 
increase in tablet diameter and/or thickness over time. Water 
uptake was measured in terms of per cent weight gain, as 
given by the equation. 
Swelling index =  X 100 
W2 = Weight of dosage form at time t. 
W1 = Initial weight of dosage form 
From the following graph, it was concluded that as the time 
increases % swelling also increases. 
Batches Diameter 
(mm)n=3 
Thickness(mm) 
n=3 
Hardness(Kg/cm2) 
n=3 
Friability(%) 
n=10 
Weight Variation 
(mg) n=20 
F1 10.00 ±0.034 6.04 ±0.012 5.5 0.78 551±1.29 
F2 10.01 ±0.023 6.04 ±0.009 6.5 0.71 550±1.37 
F3 10.01 ±0.045 6.03 ±0.002 6.5 0.70 550±1.33 
F4 10.01 ±0.052 6.02 ±0.005 6.0 0.89 549±1.22 
F5 10.02 ±0.024 6.03 ±0.009 5.5 0.77 552±1.21 
F6 10.00 ±0.039 6.02 ±0.008 6.5 0.91 550±1.19 
F7 10.00 ±0.048 6.04 ±0.003 6.0 0.85 551±1.23 
F8 10.02 ±0.021 6.03 ±0.010 6.5 0.79 550±1.49 
F9 10.01 ±0.046 6.04 ±0.011 5.5 0.80 551±1.19 
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Figure 3: Plot of swelling index against time of optimized 
formulation F1 
Buoyancy study: 
On immersion in 0.1N HCl solution pH (1.2) at 37
0
C, the 
tablets floated, and remained buoyant without disintegration.  
Fig.4 showed the results of buoyancy study and showed 
buoyancy character of prepared tablet of formulation. 
Formulation F1 shows floating lag time as 78sec. which was 
less compared to other formulations.  
Drug content uniformity 
The percentage of drug content was found to be 
between 97.01% and 99.82% of Itopride hydrochloride, 
which was within acceptable limits. Table No. 5 showed the 
results of drug content uniformity in each batch. 
 
Figure 4:In vitro buoyancy study of batch F1. 
 
Table 5: Drug content uniformity of tablets of batch F1 to F9 
 
 
 
Effect of hardness on floating lag time: 
The effect of hardness on floating lag time for batch 
F1was studied. The results of floating lag time of tablet 
having hardness of 5.5 kg/cm2, 6.5 kg/cm2 and 7.5 kg/cm2 
were 78 sec, 95sec and 120 sec respectively as tabulated in 
Table 6. Batch F1 was selected for the study because it 
showed floating lag time of 78 sec at hardness of 5.5 
kg/cm2. From this study we can conclude that as hardness 
increases, floating lag time also increases.  
Table 6: Effect of Hardness on Buoyancy Lag Time of Batch 
F1 
 
 
 
 
Figure.5: Plot of Floating lag time vs. Tablet hardness 
Effect of conc of sodium bicarbonate and citric acid on 
floating lag time:                                                                                        
The effect of conc of sodium bicarbonate and 
citric acid on buoyancy lag time for batch F1was studied. 
The results of floating lag time of tablet having conc 
sodium bicarbonate 60mg,80mg,100mg and citric acid 
50mg,60mg,70mg was  had floating lag time 120,90,78 sec 
respectively as tabulated in Table 7 . The plot of floating 
lags time (sec) vs. conc of sodium bicarbonate and citric 
acid is depicted in Fig. 2 Batch F1 was selected for the 
study because it showed buoyancy lag time of 78 sec at 
conc of sodium 100mg and citric acid 70mg. From this 
study we can conclude that as conc of sodium bicarbonate 
and citric acid increases, floating lag time also decreases. 
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Batches Drug content uniformity (%) 
F1 99.03 
F2 98.53 
F3 97.89 
F4 98.08 
F5 99.01 
F6 96.89 
F7 97.33 
F8 96.89 
F9 95.09 
Hardness Floating lag time 
5.5 kg/cm2 78 sec 
6.5 kg/cm2 95 sec 
7.5kg/cm2 120 sec 
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Table no.7: Effect of conc of sodium bicarbonate and citric acid on floating lag time 
 
 
 
 
 
 
 
Figure 6: Effect of conc of sodium bicarbonate and citric acid on floating lag time 
 
In vitro drug release study of floating tablets 
 From following graphs, we can observe 
that F1 formulation shows maximum drug release(99.40%) 
compared to other formulations. 
 
Figure 7: In vitro dissolution profile of formulations F 1 to 
F 5 
Data fitting to the model 
A two-factor, three-level optimal design as the 
response surface methodology (RSM) provides 9 runs. All 
the responses observed for 9 formulations were fitted to 
main effect model when using Design Expert (State ease – 
Ver. 8.0.7.1) and the values of R
2
 and standard deviation 
are given in Table along with the regression equation 
generated for each response. Only statistically significant 
(p < 0.05) coefficients are included in the equations. 
 
Figure 8: In vitro dissolution profile of formulations F 6 to 
F 9 
 
Table 8:Summary of Results of Regression Analysis for Response Y1, Y2, Y3 
 
 
0
20
40
60
80
100
120
140
1 2 3
Sodium bicarbonate (mg)
Citric acid(mg)
Floating lag time    (sec)                                                                                  
Sodium bicarbonate 
(mg) 
Citric 
acid(mg) 
Floating lag 
time    (sec)                                                                                   
60 50 120 
80 60 90 
100 70 78 
Response Models F value Prob > F R
2 
Adjusted R
2
 Predicted R
2 
S.D. Remarks 
Y1(Lag time) Mean  40.33 0.0017 0.9758 0.9516 0.8775 4.47 Suggested 
Y2(% release) Mean 39.00 0.0018 0.9750 0.9500 0.8734 0.91 Suggested 
Y3(Swelling Index) Mean 47.68 0.0013 0.9837 0.9649 0.8952 1.62 Suggested 
Equations:Y1=105-9.56X1-1.46X2-20.22X1X2 
Y2=93.69+1.56X1+1.44X2+2.47 X1X2 
Y3=185.78-13.78X1-2.37X2+1.04 X1X2 
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Figure 9: Effect of Xanthan gum & HPMC K4M  on lag 
time 
From above graph we can observe that, as concentration of 
xanthan gum and HPMC K4M increases, floating lag time 
also increases.So concentration of xanthan gum 50 mg and 
HPMC K4M 120 mg shows less floating lag time as 
compared to other concentrations. 
  
Figure 10: Effect of Xanthan gum & HPMC K4M  on % 
Release 
From above graph we can observe that, as concentration of 
xanthan gum and HPMC K4M increases, % release of drug 
decreases. So concentration of xanthan gum 50 mg and 
HPMC K4M 120 mg shows more % release of drug as 
compared to other concentrations. 
 
Figure 11: Effect of Xanthan gum & HPMC K4M  on 
Swelling index 
From above graph we can observe that, as concentration o 
HPMC K4M increases, swelling index also increases. So 
concentration of HPMC K4M 120 mg shows less swelling 
index as compared to other concentrations. 
CONCLUSION 
A lesser floating time and prolonged floating 
duration could be achieved by varying amount of 
effervescent mixture that is sodium bicarbonate and citric 
acid along with different polymer concentrations.The results 
of current study clearly indicate that the in vitro release of 
Itopride is significantly affected by the amount of HPMC 
K4M and Xanthan gum .HPMC K4M and Xanthan gum in 
combination help in maintaining the matrix integrity of the 
tablets. As the concentration of HPMC K4M and Xanthan 
gum increases the drug release decreases significantly; 
polymers concentration affects the drug release rate. The 
HPMC K4M and Xanthan gum in combination can be 
promising polymers for gastro retentive drug delivery 
system.  The optimized formulation of batch F1 gave the 
best in vitro release of 99 % in 12 hrs.in simulated gastric 
fluid. 
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